Description
The DELFIA® Neonatal IRT kit is designed for the quantitative determination of human immunoreactive trypsin(ogen) (IRT) in dried blood spot specimens from newborns. Used with the VICTOR2™ D Newborn Screening System, this kit provides a reliable and efficient solution to support laboratories in the early detection of cystic fibrosis (CF).
Why IRT screening matters
Cystic fibrosis is one of the most common life-limiting genetic disorders, characterized by chronic respiratory and digestive complications. Elevated levels of IRT in newborns are an early indicator of CF, making this assay a critical part of many newborn screening programs worldwide. Detecting CF early allows healthcare providers to initiate interventions that can enhance long-term outcomes for affected infants.
Proven DELFIA® technology
The DELFIA platform is recognized for its high sensitivity, robustness, and suitability for low to medium throughput screening. By combining time-resolved fluorometry with stable europium chelate labels, the system delivers:
Exceptional sensitivity and accuracy in measuring IRT levels.
Low background noise for precise signal detection.
Consistent, reproducible performance across low to medium size screening populations.
Optimized for workflow efficiency
When paired with the VICTOR2™ D system, the DELFIA Neonatal IRT kit supports streamlined and dependable screening workflows. The platform enables laboratories to process volumes of samples efficiently while minimizing manual handling. This automation not only improves productivity but also ensures the consistency and reliability required in population-based screening.
Trusted solution for newborn screening
The DELFIA Neonatal IRT kit reflects a longstanding commitment to providing screening laboratories with robust, clinically validated tools. By supporting the reliable detection of cystic fibrosis risk, the kit helps ensure newborns receive the earliest possible care for better health outcomes.
